Request Trial

Pharma news

Reset all filters
Geography
Company
Refine search
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
Pharma
Royalty Pharma: welcome clarity mixed with unwelcome ambiguity
The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.   15 May 2020
Natera and Illumina settle litigation, agree mutual licence
Pharma
Natera and Illumina settle litigation, agree mutual licence
Natera has agreed to license Illumina IP covering non-invasive prenatal testing (NIPT), in a deal that sees the pair settle all outstanding patent litigation over the technology.   14 May 2020
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
Americas
US judge dismisses attorney’s ‘opportunistic’ whistleblower suit
A Californian judge has thrown out an attorney’s whistleblower lawsuit alleging Bausch Health Companies fraudulently obtained a patent for its ulcerative colitis drug Apriso.   14 May 2020
Americas
Fed Circuit affirms generic maker’s win over Eagle
The US Court of Appeals for the Federal Circuit has affirmed a generic maker’s victory over pharmaceutical company Eagle Pharmaceuticals in a case involving cancer drug Belrapzo.   11 May 2020
Pharma
HGF promotes two to partner
IP firm HGF has appointed two patent attorneys to partner, increasing the partner group to 63 partners.   11 May 2020
Americas
Bausch Health resolves IBS patent litigation
Canada-based Bausch Health has agreed to settle its dispute with generic maker Sandoz over the latter’s attempt to release a generic version of antibiotic Xifaxan.   7 May 2020
Pharma
Will Big Pharma get the bug for microbiome therapies?
The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.   6 May 2020
Americas
Pfizer, Alibaba, Amazon, Merck unite to fight COVID-19 fraud
Criminal investigators in the US Homeland Security Investigations’ National Intellectual Property Rights Coordination Center have partnered with Pfizer, 3M, Citi, Alibaba, Amazon and Merck & Co to combat fraud and other illegal activity related to COVID-19.   6 May 2020
Asia-Pacific
Setback for Gilead in GSK HIV antiviral suit
An Australian federal judge has thrown out a challenge by Gilead Sciences to the wording of infringement claims made by a GlaxoSmithKline subsidiary.   5 May 2020
Pharma
Fraudsters will invest heavily in fake COVID-19 vaccine: Europol
Once a genuine vaccine against COVID-19 has been announced, counterfeiters and fraudsters are likely to invest heavily in offering ineffective counterfeit versions of the vaccine online, according to Europol.   1 May 2020